BASKING RIDGE, N.J. - Thursday, May 1st 2014 [ME NewsWire]
(BUSINESS
WIRE) At the AAN meeting in Philadelphia, two separate studies showed
that electroCore’s non invasive vagus nerve stimulation (nVNS) therapy
was effective in helping patients with different types of migraine. The
first poster presentation, on April 28th, found that two hours after
treatment with electroCore’s nVNS therapy patients who had both chronic
migraine and medication overuse headache were pain free in 33% of
attacks while significant pain relief (mild or no pain) was noted in 50%
of attacks. In the second poster presented on May1st it was found that
45 % of patients, with migraine without aura, were pain free within 30
minutes of just one dose of nVNS therapy.
The poster on patients with
chronic migraine and medicine overuse headache was presented by
Professor Innocenzo Rainero [P1.262] from the Department of Neuroscience
at the University of Torino, Italy. This pilot trial included 15
chronic migraine/medication overuse headache patients. All patients
underwent a five-day in-patient detoxification period and were then
followed for six months. During this period 362 migraine attacks were
treated by the patients with nVNS therapy.
Of particular importance
in this patient population, rescue medication was required in <19% of
the attacks (67/362). Side effects were mild and transient.
Professor
Rainero and colleagues concluded that nVNS with gammaCore could be an
effective and safe treatment in patients who suffer with both chronic
migraine and medication overuse headache after detoxification.
The
poster on patients with migraine without aura [P7.196] was presented by
Professor Licia Grazzi and involved 30 patients diagnosed with migraine
without aura who were being treated at the Headache Centre at the
Neurological Institute C. Besta, Milan, Italy.
The patients ranged in
age between 18-65 and were experiencing between 5-9 migraine attacks
per month. After being trained on electroCore’s gammaCore device,
patients were asked to treat 3-5 moderate to severe migraine attacks
with a single 90-second dose and record the level of pain from 30
minutes to 24 hours.
Of the 96 migraine attacks treated, 54 (56%)
experienced meaningful relief two hours after treatment, including 43
(44.8%) who were pain free within 30 minutes. In an additional 11
(11.5%) attacks, the patients reported moderate pain relief. In 42
(43.7%) attacks the nVNS therapy did not offer any relief after two
hours and patients returned to rescue medications. Treatment with
gammaCore was well tolerated and no patients reported an adverse event.
ElectroCore's
proprietary, non-invasive electrical stimulation therapy works by
activating specific fibers in the vagus nerve. This activation is
believed to cause the release of inhibitory neurotransmitters within the
central nervous system, and reduces the over expression of the
excitatory neurotransmitter glutamate, which has been implicated in a
number of different disorders.
Contacts
Vane Percy & Roberts
Simon Vane Percy
(T) +44 (0) 1737 821890
(e) simon@vanepercy.com
Permalink: http://me-newswire.net/news/10857/en
No comments:
Post a Comment